Drugs / autologous Melan-A/MART-1 specific CTL clones
autologous Melan-A/MART-1 specific CTL clones
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00720031 | Nov 2000 → May 2008 | — | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous Melan-A/MART-1 specific CTL clones | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00720031 ↗ |
| Modality | Cell therapy | “several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient” NCT00720031 ↗ |